PT-141 vs Melanotan II
Medically reviewed by the Rite Aid Health Team · Last updated August 14, 2026
PT-141 is another name used for bremelanotide, the active drug in Vyleesi. Melanotan II is an unapproved compound discussed mainly for tanning. Both affect melanocortin receptors, but they target different goals and have sharply different evidence, formulation, dosage, and access.
Get the Free Peptide Tracking Toolkit
PT-141 vs Melanotan II + many more
Explore the guide, then keep the details you verify in the Excel workbook.
Excel workbook
11 worksheets for vials, schedules, labs, storage, and more.
PDF guide
Review providers, products, documents, storage, and travel.
Free download
Useful before or after you start
- Before you start, compare the details that matter and build a focused question list.
- Already using peptides? Keep vials, administration, sites, wellness notes, labs, storage, and travel together.
- Separate your schedule from what actually happened, so important dates are easier to spot.
- Keep your private working copy on your own device.
Confirm your email to receive both downloads and your personal 20% off coupon.
Almost done
We sent the first email to .
Confirm your email to get the toolkit and your 20% off coupon.
We also sent a verification text. Reply YES to confirm your phone number.
-
1
Confirm your email
Open the first email and click the confirmation link.
-
2
Only after step 1
Then the toolkit arrives
We email your Excel workbook and PDF guide right away. Your personal 20% off coupon follows when ordering opens.
The first email should arrive within a minute. Do not see it? Check spam or promotions.
Tell us where to send it
Free, no spam, only peptide news that matters. Unsubscribe anytime.
At a glance
| Comparison | PT-141, bremelanotide | Melanotan II |
|---|---|---|
| Common goal | Labeled treatment of acquired, generalized HSDD in certain premenopausal women | Reported tanning and pigmentation |
| Mechanism | Melanocortin receptor agonist acting through central desire pathways | Melanocortin agonist with strong pigmentation effects |
| Evidence | Randomized trials and approved labeling for one indication | A three-person phase 1 study measured pigmentation and nausea; later safety concerns rely largely on reports and case studies. Phase 1 study |
| Route and timing | Subcutaneous autoinjector at least 45 minutes before anticipated sexual activity | Reported injection or nasal use |
| Dosage | Vyleesi 1.75 mg as needed; no more than once in 24 hours or eight doses monthly. Vyleesi label | No approved dosage |
| Side effects | Nausea, flushing, injection reactions, headache, blood-pressure rise, and focal pigmentation | Nausea and pigmentation occurred in early research; regulators also describe reports of changing or new moles and systemic toxicity. TGA safety review |
| Monitoring | Blood pressure, cardiovascular risk, pigmentation, nausea, and label interactions | Skin and mole changes, product quality, and systemic symptoms |
| Access and status | FDA-approved prescription autoinjector for a narrow use | Unapproved research compound |
When bremelanotide is the relevant option
Vyleesi is considered when a premenopausal woman meets the label definition of acquired, generalized hypoactive sexual desire disorder. It is not labeled for men, postmenopausal women, or performance enhancement.
Why Melanotan II is a different decision
Melanotan II use centers on pigmentation rather than an approved sexual-health indication. An early three-person study recorded pigmentation and nausea. An Australian regulator later summarized reports involving mole changes, systemic toxicity, dosing errors, and contaminated products. Sources: Melanotan II phase 1 study, TGA safety review
Why they should not be combined
Both stimulate melanocortin pathways and can produce nausea, flushing, and pigmentation changes. No approved or evidence-based regimen combines them, and overlapping effects can increase risk without a defined benefit.
Related
Sources
Get the Free Peptide Tracking Toolkit
PT-141 vs Melanotan II + many more
Explore the guide, then keep the details you verify in the Excel workbook.
Excel workbook
11 worksheets for vials, schedules, labs, storage, and more.
PDF guide
Review providers, products, documents, storage, and travel.
Free download
Useful before or after you start
- Before you start, compare the details that matter and build a focused question list.
- Already using peptides? Keep vials, administration, sites, wellness notes, labs, storage, and travel together.
- Separate your schedule from what actually happened, so important dates are easier to spot.
- Keep your private working copy on your own device.
Confirm your email to receive both downloads and your personal 20% off coupon.
Almost done
We sent the first email to .
Confirm your email to get the toolkit and your 20% off coupon.
We also sent a verification text. Reply YES to confirm your phone number.
-
1
Confirm your email
Open the first email and click the confirmation link.
-
2
Only after step 1
Then the toolkit arrives
We email your Excel workbook and PDF guide right away. Your personal 20% off coupon follows when ordering opens.
The first email should arrive within a minute. Do not see it? Check spam or promotions.
Tell us where to send it
Free, no spam, only peptide news that matters. Unsubscribe anytime.
For general education only — not medical advice or a treatment recommendation. Peptides are not a substitute for care from a licensed provider. Talk to a qualified healthcare professional before you start, stop, or change any peptide, medication, or supplement.
FAQ
Bremelanotide is FDA approved as Vyleesi for a specific form of HSDD in premenopausal women. Marketplace PT-141 is not automatically the approved product.
No. It is a different melanocortin compound without an approved clinical use.